Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
The Pharma Data
MARCH 7, 2022
“The launch of our first generic version of Revlimid® in the U.S. This product adds to our broad generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, as defined by the World Health Organization.”. Call your doctor for medical advice about side effects. About Teva.
Let's personalize your content